UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 384

Sortiert nach

Engineered RBCs Encapsulating Antigen Induce Multi-Modal Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Frontiers in immunology, 2022-04, Vol.13, p.869669

2022

Volltextzugriff (PDF)

Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice

Frontiers in immunology, 2022-10, Vol.13, p.1015585-1015585

2022

Volltextzugriff (PDF)

693 SQZ-AAC-HPV-101: initial data from a phase I dose escalation/expansion study of SQZ-AAC-HPV, a red blood cell-based therapeutic cancer vaccine for HPV16+ solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A785-A785

2023

Volltextzugriff (PDF)

594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+ tumors treated with cell-based vaccine, SQZ-PBMC-HPV

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A676-A676

2023

Volltextzugriff (PDF)

692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A784-A784

2023

Volltextzugriff (PDF)

165 Activating antigen carriers generated with microfluidics cell squeezing drive effective anti-tumor responses

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A98-A99

2020

Volltextzugriff (PDF)

Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography

Journal of controlled release, 2005-11, Vol.108 (1), p.21-32

2005

Volltextzugriff (PDF)

156 RBC-derived, activating antigen carriers (SQZ AACs) prime potent T cell responses and drive tumor regression in vivo

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A166-A166

2021

Volltextzugriff (PDF)

211 SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A224-A224

2021

Volltextzugriff (PDF)

Local anesthetics and mode of delivery : Bupivacaine versus ropivacaine versus levobupivacaine

Anesthesia and analgesia, 2007-09, Vol.105 (3), p.756-763

2007

Volltextzugriff (PDF)

170 Microfluidics cell squeezing enables potent cellular vaccines in murine models through direct cytosolic loading and direct CD8 T cell priming

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A102-A102

2020

Volltextzugriff (PDF)

Noncompaction Cardiomyopathy: Case Report and Echocardiographic Findings

Journal of cardiothoracic and vascular anesthesia, 2009-04, Vol.23 (2), p.200-202

2009

Volltextzugriff (PDF)

Abstract 1524: Peripheral blood mononuclear cells engineered via microfluidic Cell Squeeze® technology to generate APCs that drive mutant-KRas-specific CD8+ T cell responses

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1524-1524

2021

Volltextzugriff (PDF)

Formation of microparticulate protein powder using a supercritical fluid antisolvent

Biotechnology and bioengineering, 1993-02, Vol.41 (3), p.341-346

1993

Volltextzugriff (PDF)

Abstract 1525: Enhancing potency of antigen presenting cells via signal 2/3 mRNA engineering through Cell Squeeze® technology

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1525-1525

2021

Volltextzugriff (PDF)

Abstract 1523: Cell Squeeze® delivery of antigen-encoding mRNA enables human PBMCs to drive antigen-specific CD8+ T cell responses for diverse clinical applications

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1523-1523

2021

Volltextzugriff (PDF)

Abstract 1445: Tumor-specific T cell engineering for enhanced effector function via microfluidic delivery of bioactive molecules

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1445-1445

2019

Volltextzugriff (PDF)

Abstract 3187: Engineering a new generation of cell therapies for solid tumor oncology using the SQZ platform

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3187-3187

2019

Volltextzugriff (PDF)

1743-P: Engineering Erythrocytes with the SQZ Cell Therapy Platform to Enhance Immunotolerance

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Volltextzugriff (PDF)

573. Vector Free Genome Editing of Immune Cells for Cell Therapy

Molecular therapy, 2016-05, Vol.24, p.S229-S229

2016

Volltextzugriff (PDF)

The automated malnutrition assessment

Nutrition (Burbank, Los Angeles County, Calif.), 2013, Vol.29 (1), p.113-121

2013

Volltextzugriff (PDF)

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2536-2536

2021

Volltextzugriff (PDF)

Subarachnoid Small-Dose Bupivacaine Versus Lidocaine for Cervical Cerclage

Anesthesia and analgesia, 2003-07, Vol.97 (1), p.56-61

2003

Volltextzugriff (PDF)

Vector-Free Engineering of Antigen Presenting Cells for Adoptive Immunotherapies for the Treatment of Cancer

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.73-73.18

2017

Volltextzugriff (PDF)

1 – 25 von 384

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(310)
Mit Volltextzugriff
(296)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(383)
Japanisch
(34)

Erscheinungsjahr

n.n

Thema

Science & Technology
(199)
Life Sciences & Biomedicine
(180)
Humans
(155)
Female
(90)
Biological And Medical Sciences
(88)
Male
(76)
Medical Sciences
(69)
Adult
(57)
Middle Aged
(38)
Animals
(35)
Aged
(30)
Pregnancy
(25)
Adolescent
(24)
Child
(23)
Prospective Studies
(22)
Fundamental And Applied Biological Sciences. Psychology
(20)
Mice
(20)
Immunology
(19)
Neurosciences & Neurology
(19)
Pharmacology. Drug Treatments
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Engineered RBCs Encapsulating Antigen Induce Multi-Modal Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice

693 SQZ-AAC-HPV-101: initial data from a phase I dose escalation/expansion study of SQZ-AAC-HPV, a red blood cell-based therapeutic cancer vaccine for HPV16+ solid tumors

594 SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+ tumors treated with cell-based vaccine, SQZ-PBMC-HPV

692 COMMANDER-001: safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors

165 Activating antigen carriers generated with microfluidics cell squeezing drive effective anti-tumor responses

Porous PLGA microparticles: AI-700, an intravenously administered ultrasound contrast agent for use in echocardiography

156 RBC-derived, activating antigen carriers (SQZ AACs) prime potent T cell responses and drive tumor regression in vivo

211 SQZ™ eAPCs generated from PBMCs by delivery of multiple mRNAs encoding for antigens, costimulatory proteins, and engineered cytokines

Local anesthetics and mode of delivery : Bupivacaine versus ropivacaine versus levobupivacaine

170 Microfluidics cell squeezing enables potent cellular vaccines in murine models through direct cytosolic loading and direct CD8 T cell priming

Noncompaction Cardiomyopathy: Case Report and Echocardiographic Findings

Abstract 1524: Peripheral blood mononuclear cells engineered via microfluidic Cell Squeeze® technology to generate APCs that drive mutant-KRas-specific CD8+ T cell responses

Formation of microparticulate protein powder using a supercritical fluid antisolvent

Abstract 1525: Enhancing potency of antigen presenting cells via signal 2/3 mRNA engineering through Cell Squeeze® technology

Abstract 1523: Cell Squeeze® delivery of antigen-encoding mRNA enables human PBMCs to drive antigen-specific CD8+ T cell responses for diverse clinical applications

Abstract 1445: Tumor-specific T cell engineering for enhanced effector function via microfluidic delivery of bioactive molecules

Abstract 3187: Engineering a new generation of cell therapies for solid tumor oncology using the SQZ platform

1743-P: Engineering Erythrocytes with the SQZ Cell Therapy Platform to Enhance Immunotolerance

573. Vector Free Genome Editing of Immune Cells for Cell Therapy

The automated malnutrition assessment

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101

Subarachnoid Small-Dose Bupivacaine Versus Lidocaine for Cervical Cerclage

Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8 + T Cell Responses with Antitumor Activity

Vector-Free Engineering of Antigen Presenting Cells for Adoptive Immunotherapies for the Treatment of Cancer

Aktive Filter

Suchergebnisse filtern